Here’s what you should know:
1. The surgical endoscopy firm will use the funds to expand into the U.S.
2. Speedboat, the company’s flagship device, is already FDA-approved. The endoscope was designed to remove tumors and lesions from the gastrointestinal tract in less than an hour.
3. Creo Medical Group is exploring a series of potential mergers and acquisitions to expand its production capabilities.
4. Creo Medical Group CEO Craig Gulliford said, “The monies raised will enable us to accelerate our commercialization strategy, complete the development of our existing surgical suite of minimally invasive instruments and develop new products, as well as attract partners and enable the potential for strategic mergers and acquisitions.”
Editor’s note: The conversation was calculated at the time of publication, not the time the transaction took place.
More articles on gastroenterology:
From adding in-network payer contracts to more total joints in ASCs: 6 CEOs on where their companies are headed in the next 6 months
4 overlooked aspects of HIPAA compliance for ophthalmic ASCs
Alexandria Eye Clinic partners with Vance Thompson Vision — 4 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
